145 related articles for article (PubMed ID: 9479580)
21. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.
Liu X; Jiang S; Fang C; Yang S; Olalere D; Pequignot EC; Cogdill AP; Li N; Ramones M; Granda B; Zhou L; Loew A; Young RM; June CH; Zhao Y
Cancer Res; 2015 Sep; 75(17):3596-607. PubMed ID: 26330166
[TBL] [Abstract][Full Text] [Related]
22. Effector mechanisms of therapeutic antibodies against ErbB receptors.
Peipp M; Dechant M; Valerius T
Curr Opin Immunol; 2008 Aug; 20(4):436-43. PubMed ID: 18585454
[TBL] [Abstract][Full Text] [Related]
23. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
24. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
25. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
[TBL] [Abstract][Full Text] [Related]
26. ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.
Yasmeen A; Bismar TA; Al Moustafa AE
Future Oncol; 2006 Dec; 2(6):765-81. PubMed ID: 17155902
[TBL] [Abstract][Full Text] [Related]
27. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
28. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
Ding L; Tian C; Feng S; Fida G; Zhang C; Ma Y; Ai G; Achilefu S; Gu Y
Theranostics; 2015; 5(4):378-98. PubMed ID: 25699098
[TBL] [Abstract][Full Text] [Related]
29. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
30. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
Gilbertson RJ; Bentley L; Hernan R; Junttila TT; Frank AJ; Haapasalo H; Connelly M; Wetmore C; Curran T; Elenius K; Ellison DW
Clin Cancer Res; 2002 Oct; 8(10):3054-64. PubMed ID: 12374672
[TBL] [Abstract][Full Text] [Related]
31. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
32. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
Sanderson MP; Dempsey PJ; Dunbar AJ
Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic growth factor receptors: implications for signal transduction therapy.
Mosesson Y; Yarden Y
Semin Cancer Biol; 2004 Aug; 14(4):262-70. PubMed ID: 15219619
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional regulation of signal regulatory protein alpha1 inhibitory receptors by epidermal growth factor receptor signaling.
Kapoor GS; Kapitonov D; O'Rourke DM
Cancer Res; 2004 Sep; 64(18):6444-52. PubMed ID: 15374953
[TBL] [Abstract][Full Text] [Related]
36. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
37. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
38. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC
Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396
[TBL] [Abstract][Full Text] [Related]
39. Receptor-targeted cancer therapy.
Richter M; Zhang H
DNA Cell Biol; 2005 May; 24(5):271-82. PubMed ID: 15869404
[TBL] [Abstract][Full Text] [Related]
40. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
Arteaga CL
J Clin Oncol; 2001 Sep; 19(18 Suppl):32S-40S. PubMed ID: 11560969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]